IL6 and neoplasm: This marked elevation suggests that while gefitinib effectively targets EGFR signaling, it may concurrently activate compensatory or stress-related pathways that drive IL-6 production—a cytokine known to support tumor growth, immune evasion, and therapeutic resistance.